Compare CNNE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | IVA |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.6M | 737.1M |
| IPO Year | 2017 | 2020 |
| Metric | CNNE | IVA |
|---|---|---|
| Price | $15.92 | $2.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $17.25 | $15.20 |
| AVG Volume (30 Days) | 452.9K | ★ 2.6M |
| Earning Date | 11-09-2026 | 09-28-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $499,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.87 | N/A |
| P/E Ratio | $132.00 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $2.82 |
| 52 Week High | $18.87 | $7.98 |
| Indicator | CNNE | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 36.32 |
| Support Level | $15.08 | N/A |
| Resistance Level | $16.45 | $4.80 |
| Average True Range (ATR) | 0.36 | 0.21 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 69.83 | 18.72 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.